TY-Jour T1 - NTM模块的初步验证：患有肺结核患者的患者报告的结果措施JF - 欧洲呼吸期刊Jo - EUR RESPIR J Do - 10.11.1300-2019 VL - 55 IS - 1 SP -1901300 AU - Henkle，Emily Au - Winthrop，Kevin L. Au - Ranches，Gregory P. Au - Plinke，Wesley Au - Litvin，Hana K. Au - Quittner，Alexandra L. Y1 - 2020/01/01 UR - http：//www.qdcxjkg.com/content/55/1/1901300.abstract n2 - 介绍Nontuberuly的分枝杆菌（NTM）引起慢性，衰弱的肺病。患者报告的结果提供症状，运作和治疗反应的措施。在这里，我们描述了最近开发的NTM模块的初步验证。方法中的研究人群包括西北部的NTM Biobank患者，其中分枝杆菌（Mac）被孤立，谁遇到了美国肺病的2007年美国胸部社会/传染病学会标准。NTM模块在注册和12个月内施用;子集还完成了寿命质量 - 支气管扩张（QOL-B）。NTM模块生成四个域分数（0-100;更高的分数，表明更好的功能）反映了NTM特异性症状（NTM症状，身体图像，消化症状和饮食问题）。我们描述了患者的特征和平均分数，并评估了对每个结构域的12个月对治疗的心理测量性质，包括对治疗的反应。结果总体而言，包括203例肺部MAC疾病患者。平均入学评分范围从76（NTM症状）到84（饮食问题）。 Ceiling effects were observed for Body Image (26% of participants) and Eating Problems (52%). Internal consistency (Cronbach's alpha) ranged from 0.67 (Digestive Symptoms) to 0.89 (Eating Problems). The intraclass correlation for test–retest reproducibility (n=27) ranged from 0.72 (Body Image) to 0.94 (Eating Problems). Patients starting treatment (n=35) had statistically significant increases in scores for NTM Symptoms (+5, p=0.04), Digestive Symptoms (+7, p=0.002), Body Image (+7, p=0.03) and QOL-B Respiratory Symptoms (n=25, +10, p=0.006). NTM Symptoms scores increased by 15 points (p=0.002) in the 16 patients with scores ≤80 at enrolment.Conclusion The NTM Module generally performs well as a valid patient-reported outcome for pulmonary MAC disease and was responsive to MAC treatment.The NTM Symptom Module is a valid patient-reported outcome tool that can facilitate patient-centred care and may be used as an outcome in clinical trials to support labelling claims for regulatory bodies. http://bit.ly/2nwlPgi ER -